Xarelto and Invega Patient Assistance: an application guide for practices
Johnson & Johnson runs patient assistance for Xarelto and Invega through a single enrollment form covering its patient assistance foundation range. It requires prescriber certification, the patient’s consent and signature, and proof of household income.
Are you a patient? Start with the prescribing practice and use the official manufacturer link above for current program information. AlgoMeds cannot determine eligibility or check an application for you.
One application covers Xarelto and Invega
One document covers both, despite the two drugs having almost nothing else in common: an oral anticoagulant prescribed across cardiology and primary care, and a long-acting injectable antipsychotic given in the clinic.
Each patient needs their own enrollment and the prescriber certifies the specific product, but the form a coordinator opens is the same one.
The practical consequence is that a health system running both is running one paperwork process, not two, and can staff it that way.
| Brand | Generic | Used for | How it is given |
|---|---|---|---|
| Xarelto | rivaroxaban | reducing stroke risk in non-valvular atrial fibrillation and treating or preventing venous thromboembolism | Dispensed to the patient, usually through a pharmacy |
| Invega | paliperidone palmitate | schizophrenia and schizoaffective disorder, as a long-acting injectable | Administered in the practice on a recurring schedule |
Eligibility factors to verify
Johnson & Johnson sets the eligibility criteria for the Xarelto and Invega program and changes them, so the categories below are only the ones programs of this kind generally assess.They are not the criteria for this program, confirm current requirements onJohnson & Johnson’s official program pagebefore telling a patient anything. We do not publish income thresholds for Xarelto and Invega here, because a stale number on a marketing page is how a practice ends up telling a patient the wrong thing.
- Insurance status, generally aimed at patients who are uninsured, or insured but unable to access the medication through their coverage.
- Household income against the program’s own published threshold, evidenced by documentation rather than attestation.
- Residency and prescriber licensure requirements set by the program.
- A prescription written for an indication the program covers, certified by the prescribing clinician.
What the application needs
A complete Xarelto and Invega application is assembled from the four parts below, and because Xarelto and Invega is dispensed to the patient, usually through a pharmacy, the part most likely to hold it up is the one this practice controls least. Missing any one of them is what sends a form back rather than forward.
| Part | Who owns it | What it contains |
|---|---|---|
| Prescriber section | Prescribing clinician | Diagnosis, treatment plan, prescribed regimen, prescriber credentials and NPI, and the certification signature. |
| Patient section | Patient or verified legal representative | Demographics, contact and shipping details, insurance status, household information, program consent and the patient’s signature. |
| Income documentation | Patient | Documentary evidence of household income, in whichever forms the program accepts. |
| Program-specific attachments | Practice | Whatever else this specific program requires. Requirements differ between programs and change over time. |
Where practices get stuck
Common workflow challenges for these programs:
- The two drugs are administered in opposite ways (one dispensed to the patient, one given in the clinic on a fixed interval), so the same form sits inside two very different workflows.
- Anticoagulants are prescribed across cardiology, primary care and post-surgical follow-up, so no single team owns the assistance workflow.
- For Invega, a missed enrollment window maps to a specific appointment and a specific missed dose rather than a gradual gap.
- Invega patients frequently have a legal representative or case manager acting for them, and that authority needs a real path rather than a workaround.
- The patients most likely to need assistance for either drug are often the hardest to reach for a signature.
How long an application takes
We do not publish a turnaround figure for Xarelto and Invega, because Johnson & Johnson sets it and it moves. What a practice can control is the work before submission. Four factors commonly affect the timeline: how long the patient section takes to return, how many review cycles occur between staff and the prescriber, whether the submission is complete on the first attempt, and the manufacturer review time, which we do not estimate.
How AlgoMeds handles it for Xarelto and Invega
AlgoMeds opens the correct current Xarelto form, including variant forms that depend on indication, already filled from the patient chart, prescriber profile, insurance on file and prior submitted applications. The patient signs from a single-use, identity-verified link sent by text message, with no account required. This can reduce printing and scanning. Required documents are checked before submission, the application is tracked to a decision, and renewals open ahead of expiry using information from the prior application.
For Xarelto and Invega, as for every program, AlgoMeds does not determine eligibility, predict approval, or claim to improve the odds of a decision going a particular way. It removes the paperwork between a clinical decision and a submittedXarelto and Invega application, nothing more, and nothing that touches the manufacturer’s judgement.See the full coordinator workflow.
Xarelto and Invega patient assistance: frequently asked questions
Why would an anticoagulant and a long-acting injectable use the same application?
Because the form belongs to the manufacturer’s patient assistance foundation rather than to a single product. The foundation assesses the patient, so one enrollment form serves the range. Confirm current requirements on the official program page.
How is a legal representative handled on the application?
A verified legal representative has a defined role in the form, with identity verified before anything is disclosed and their authority recorded on the application rather than assumed informally.
Related program guides
Practices working with this program may also work with these programs. See the full program directory, or thecardiometabolic overview.
Xarelto and Invega are registered trademarks of Johnson & Johnson or its affiliates. AlgoMeds is not affiliated with, endorsed by, or sponsored by Johnson & Johnson. Program details are subject to change. Confirm current requirements with the official program before applying.
This page is general information for medical practices about a manufacturer program. It is not medical advice, not legal advice, and not a determination of eligibility. AlgoMeds does not host or reproduce manufacturer enrollment forms on this website.
Stop retyping the Xarelto form.
Supported fields are filled from practice records, patients can sign from a text message, and staff can track each application from one workflow.